• vcard
D 314.552.6876
F 314.754.8390
  • Education
    • LL.M., Washington University in St. Louis
    • J.D., Washington University in St. Louis
    • B.A., Knox College
Andrew Hoyne practices business and corporate law focused upon the representation of life sciences and other technology-based companies. His clients include/have included multi-billion dollar corporations, Big Ten universities, emerging companies and investors. Andy's life science practice includes pharmaceuticals, medical devices, research services, chemical and biochemical products, agriculture, and bio-energy clients. He has also represented clients in the fields of energy; information technology; food products, ingredients and flavors; electric motors; imaging devices; powders for industrial applications; spectroscopic analytical technology; and other technical and industrial applications.

Andy also represents venture capital funds as well as corporate and other investors with respect to fund investment, structure and management in the areas of life sciences, information technology, financial technology, cyber security, agriculture and energy.

Prior to entering private practice, Andy was associate general counsel for Invitron, a publicly-held bio-pharmaceutical contract manufacturing and product development company, and assistant general counsel for The Seven-Up Company, a soft drink and food products company. From 2011-2015, Andy was the practice leader for the Startup Ventures practice segment in Polsinelli’s St. Louis office. He also served as one of the co-leaders of the firm’s national Startup Ventures practice segment.
  • Mr. Hoyne has represented his clients in transactions totaling hundreds of millions of dollars. Over the past dozen years, he has represented his clients in helping them raise over $100 million of financing fromventure capital funds, angels, development organizations and other funding sources.
  • Mr. Hoyne has represented his clients in partnering agreements with Monsanto, Zimmer, Sangamo and other companies. Client exits have included sales to Monsanto, Viasys (now part of Carefusion) and Avant Pharmaceuticals.
  • Mr. Hoyne represents the technology ventures group of a multi-billion corporation that invests in relevant new technologies, including investments in the United States, Canada and Europe. He also represents a venture capital fund with respect to its portfolio investments.
  • Mr. Hoyne is an active member of the firm's multi-disciplinary emerging technology company practice that assists clients in a variety of technical fields including information technology, life sciences, and energy.